EXO1 protects BRCA1-deficient cells against toxic DNA lesions
Bert van de Kooij,Anne Schreuder,Raphael Pavani,Veronica Garzero,Sidrit Uruci,Tiemen J Wendel,Arne van Hoeck,Marta San Martin Alonso,Marieke Everts,Dana Koerse,Elsa Callen,Jasper Boom,Hailiang Mei,Edwin Cuppen,Martijn S Luijsterburg,Marcel A T M van Vugt,André Nussenzweig,Haico van Attikum,Sylvie M Noordermeer,Tiemen J. Wendel,Martijn S. Luijsterburg,Marcel A.T.M. van Vugt,Sylvie M. Noordermeer
DOI: https://doi.org/10.1016/j.molcel.2023.12.039
IF: 16
2024-01-25
Molecular Cell
Abstract:Summary Inactivating mutations in the BRCA1 and BRCA2 genes impair DNA double-strand break (DSB) repair by homologous recombination (HR), leading to chromosomal instability and cancer. Importantly, BRCA1/2 deficiency also causes therapeutically targetable vulnerabilities. Here, we identify the dependency on the end resection factor EXO1 as a key vulnerability of BRCA1-deficient cells. EXO1 deficiency generates poly(ADP-ribose)-decorated DNA lesions during S phase that associate with unresolved DSBs and genomic instability in BRCA1-deficient but not in wild-type or BRCA2-deficient cells. Our data indicate that BRCA1/EXO1 double-deficient cells accumulate DSBs due to impaired repair by single-strand annealing (SSA) on top of their HR defect. In contrast, BRCA2-deficient cells retain SSA activity in the absence of EXO1 and hence tolerate EXO1 loss. Consistent with a dependency on EXO1-mediated SSA, we find that BRCA1 -mutated tumors show elevated EXO1 expression and increased SSA-associated genomic scars compared with BRCA1-proficient tumors. Overall, our findings uncover EXO1 as a promising therapeutic target for BRCA1-deficient tumors.
cell biology,biochemistry & molecular biology